ProTgen is advancing first-in-class targeted Notch activators that generate progenitor T cells to restore thymic function and immune competence across ex vivo and in vivo programs.

ProTgen is developing a platform that uses hematopoietic stem cells to generate progenitor T (proT) cells in vitro, using their proprietary differentiation method and reagent that make 3D-cultures …

Protgen Company is dedicated to the research and development of recombinant protein drugs and in vitro diagnostic reagents, exploring the mechanisms of tumorigenesis and metastasis, aging, …

ProTgen is a biotechnology company developing a new class of transformative medicines designed to restore immune competence by unlocking the therapeutic potential of the Notch signaling pathway.

Protgen is an important component unit of the National Engineering Research Center for Protgen Technology.

Jun 24, 2026 · Backed by top-tier investors and a world-class team of experts, ProTgen is advancing a pipeline leveraging targeted Notch activators with the potential to provide foundational new …

ProtaGene offers state-of-the-art cell-based assays to evaluate the efficacy and safety of your product and develops new molecule-specific assays tailored to your individual requirements.

Protgen Company was founded in August 2004. It is a research-oriented high-tech enterprise founded by overseas returnees and undertakes the industrial transformation tasks of various scientific …

Information on valuation, funding, cap tables, investors, and executives for Protgen. Use the PitchBook Platform to explore the full profile.

On April 8th, 2017, Malice-Risu invented the "Protogen" species, an extension of the Primagen which is notably less artificial, being about 40 percent artificial vs. 60 percent organic.